Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Social Media
Drones
Disney
Work
Donald Trump
Formula 1
Premier League
Natural Disasters
Artificial Intelligence
Gold
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial

Summary by dermatologytimes.com
Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearanc for a phase 1 trial for mild to moderate psoriasis.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
dermatologytimes.comdermatologytimes.com

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial

Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearanc for a phase 1 trial for mild to moderate psoriasis.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in on Thursday, May 22, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal